In Finland, the oasis of drug development – the commercialization requires resources

From the reader. Finland could be an oasis of drug development. In our country, high -quality medical research is being conducted in our country, and our health register offers an exceptional competitive advantage.

Still, we do not create enough international breakthroughs – jammy successes that revolutionize the market and bring new economic growth to Finland. Factors and funding are needed for the industry.

Now prefer development attempts to get out of sales

Risto Murron The Working Party’s Growth Report presents a solution to the problem. Namely, Finnish registry material provides an exceptional strong competitive advantage for the work in many areas, and the state can promote the use of this competitive advantage through national coordination.

There are many reasons for growing health companies in Finland. In addition to health register information, our country also has the opportunity to utilize disease monitoring information and samples.

The small amount of the R&D section of the folk product is easily annoyed. However, Finnish research levels and patenting activity are at a good level internationally.

Also, the emergence of small -scale new companies is at a satisfactory level, but where are the breakthroughs created through research – the successes? I am now talking about individual products that are more than a billion in turnover.

Ten times more drugs are sold abroad than in Finland. Similarly, five times more from Sweden.

The Covid-19 pandemia showed Finland’s poor preparation for significant health challenges. Finland is a small pharmaceutical market, which is why without special measures, it is not self -evident that new medicines will be made available to our citizens through international pharmaceutical giants.

If the development of new drugs is not a national target, the nation takes a significant risk for the well -being of its citizens.

The realization of risk investments requires an understanding of the product’s sales potential. The product to be developed through market understanding can build probability models of success.

Few industrial sectors use as much historical development as medicines. Drug development is also the subject of continuous authority examination, ensuring the development of the development models.

All of this allows you to use the so -called NPV (NPV) model. This model does not work in Finland at all like America. Unfortunately, this inactivity favors development companies off the sale as soon as it is possible – usually too early. There are very few coins in the Finnish maid’s purse with early sales.

More international sting products

The pharmaceutical and health technology sector is a profound and research-intensive industry. Finland is well supported by medical research, but there is no longer any funding or factors in commercialization and pursuit of world class.

The two Jymy products developed in Finland (Mirena and Nubeqa) provide extensive net sales to their developers, even though the sale of both is done by a foreign pharmaceutical giant.

More of these, the maid of Finland remains beautiful and healthy. This way, you could afford to pay bills in the national economy.

Markku Jalkanen

bioneer